ROHTO Pharmaceutical Forges Global Aesthetics Market Entry Through Long-Term Strategic and Equity Partnership with EMA Aesthetics

ROHTO Pharmaceutical Strengthens Global Presence with EMA Aesthetics Through Strategic Partnership

EMA Aesthetics, a Dublin-based global aesthetics company, has announced a significant strategic and equity collaboration with ROHTO Pharmaceutical, a renowned Japanese multinational recognized for its innovative approaches in healthcare and skincare, along with its European affiliate Rohto Mediluxe Europe.

This strategic alliance marks ROHTO’s entry into the medical aesthetics sector, amplifying the growth of EMA Aesthetics in the rapidly expanding global market. The collaboration involves joint research and development efforts to enhance existing and introduce new aesthetic products. It serves as a pivotal step for ROHTO to extend its presence in the aesthetics industry beyond Japan, underscoring its dedication to capitalizing on the substantial expansion in the aesthetics sectors within the EU and US, throughout 2024 and beyond.

Malcolm Wall Morris, Co-Founder and CEO of EMA Aesthetics, expressed his enthusiasm, stating, “EMA Aesthetics, a trailblazer in aesthetic products since its inception in 2019, has consistently pursued innovation. Our commitment to surpass industry norms aligns seamlessly with ROHTO’s ethos. This partnership marks a crucial juncture, positioning us to push the boundaries of aesthetic products globally.”

Nobuhiro Hirasawa, CEO of ROHTO Mediluxe Europe (Rohto MLE), representing medical aesthetic business in EMEA for ROHTO Pharmaceutical, added, “I am thrilled to confirm our involvement in this exciting venture as ROHTO celebrates its 125th anniversary. This collaboration merges EMA’s disruptive innovation with ROHTO’s customer-focused approach, creating a harmonious blend where cutting-edge technology meets robust research and development. I am confident this partnership will lead to exceptional value creation and look forward to working with both teams.”

This investment not only strengthens ROHTO’s position in EMEA but also extends its footprint into the US and other markets. EMA and ROHTO will jointly concentrate on developing products that provide excellent patient results and an enhanced user experience for clinics and therapists.

The global aesthetic medicine sector, leading the rapid growth of the beauty and personal care products market, exceeding $500 billion in 2022, is anticipated to witness a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030. APAC currently commands a dominant revenue share of 39%, poised for rapid expansion.

Source link